Moreover, the CRCS1 subgroup exhibited higher scores in the Tumor Immune Dysfunction and Exclusion (TIDE) and ENHss analyses, while CRCS2 scored higher in EREG.EXPss and HRD (Figure 4D). This evidence concerns the gene GALNT12 and neoplasm.